Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study †
Titel:
Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study †
Auteur:
Monk, B.J. Ghatage, P. Parekh, T. Henitz, E. Knoblauch, R. Matos-Pita, A.S. Nieto, A. Park, Y.C. Cheng, P.S. Li, W. Favis, R. Ricci, D. Poveda, A.